SCHEMBL649044

SCHEMBL649044

O=C(O)CCC(=O)Nc1ncc(/C=C2\S/C(=N\c3ccc(C(=O)O)cc3)NC2=O)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.46
KMT2A Q03164 7/20 0.46
POLB P06746 5/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 1/20 0.42
PTPN7 P35236 2/20 0.41
DUSP3 P51452 2/20 0.41
PTPN12 Q05209 2/20 0.41
PTPN22 Q9Y2R2 2/20 0.41
PTPN5 P54829 1/20 0.41
PTPN11 Q06124 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 2/20 0.41
CHRM5 P08912 1/20 0.41
GPR35 Q9HC97 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649045 1.00 MEN1 (0.46) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL650807 0.92 SYK (0.48) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL649726 0.92 SYK (0.48) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL653260 0.92 NPC1 (0.50) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL653261 0.92 NPC1 (0.50) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL651131 0.90 POLB (0.45) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL651137 0.90 POLB (0.45) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL651435 0.90 POLB (0.54) MEN1KMT2APOLBMAPTLMNA
SCHEMBL651434 0.90 POLB (0.54) MEN1KMT2APOLBMAPTLMNA
SCHEMBL653120 0.89 MAPT (0.52) MEN1KMT2APOLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MEN1 1406/4885KMT2A 3437/4885POLB 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.